www.renovo.com
Renovo (LSE:RNVO) is a biopharmaceutical product company and a leader in the discovery and development of drugs to reduce scarring, improve wound healing and enhance tissue regeneration.
Renovo Group: Brooke to succeed Ferguson as chairman
Renovo Group (LON:RNVO) told investors that non-executive director Jamie Brooke will succeed Professor Mark WJ Ferguson as chairman of the company on January 15 this year.
Professor Ferguson is resigning from his role as non- exec chairman and consultant on the same day.
He has been appointed Director General of Science Foundation Ireland (SFI) with effect from January 16, Renovo said in a statement.
The Renovo board will now comprise a non-executive chairman, non-exec director and a finance director, it added.
Based in Dublin, SFI invests in world class research in areas of strategic importance and strength to the Irish economy.
Since its foundation in 2000, it has invested 1.4 billion Euros in research projects and currently funds over 900 active research projects and a community of over 3000 researchers.
Professor Ferguson said he was looking forward to ensuring that research output was appropriately exploited by small, medium and large companies to create jobs and companies which will contribute to economic growth in Ireland.
Also in the statement, Brooke wished Professor Ferguson well for the future and thanked him for his invaluable contribution to Renovo.



















